These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37502925)

  • 1. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Res Sq; 2023 Jul; ():. PubMed ID: 37502925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
    Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
    Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
    Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review.
    Gao L; Shen X; He L; Wu J; Liu Y; Wang X; Shao X
    Ann Transl Med; 2022 Jan; 10(2):117. PubMed ID: 35282060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD63
    Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
    Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
    Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
    Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER
    Soria-Bretones I; Thu KL; Silvester J; Cruickshank J; El Ghamrasni S; Ba-Alawi W; Fletcher GC; Kiarash R; Elliott MJ; Chalmers JJ; Elia AC; Cheng A; Rose AAN; Bray MR; Haibe-Kains B; Mak TW; Cescon DW
    Sci Adv; 2022 Sep; 8(36):eabq4293. PubMed ID: 36070391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
    Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
    Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
    Al-Qasem AJ; Alves CL; Ehmsen S; Tuttolomondo M; Terp MG; Johansen LE; Vever H; Hoeg LVA; Elias D; Bak M; Ditzel HJ
    NPJ Precis Oncol; 2022 Sep; 6(1):68. PubMed ID: 36153348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.
    Petrossian K; Kanaya N; Lo C; Hsu PY; Nguyen D; Yang L; Yang L; Warden C; Wu X; Pillai R; Bernal L; Huang CS; Kruper L; Yuan Y; Somlo G; Mortimer J; Chen S
    Oncotarget; 2018 Jun; 9(45):27736-27751. PubMed ID: 29963233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
    Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
    Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER
    Shee K; Jiang A; Varn FS; Liu S; Traphagen NA; Owens P; Ma CX; Hoog J; Cheng C; Golub TR; Straussman R; Miller TW
    FASEB J; 2019 Feb; 33(2):1644-1657. PubMed ID: 30161001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Allotta A; Servetto A; Ciciola P; Pesapane A; Ascione CM; Napolitano F; Di Mauro C; Vigliar E; Iaccarino A; De Angelis C; Bianco R; Formisano L
    NPJ Breast Cancer; 2023 May; 9(1):48. PubMed ID: 37258566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
    Liu W; Zhang R; Yu X; Zhang Y; Kang T; Liao D
    Med Oncol; 2023 Aug; 40(9):267. PubMed ID: 37567972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.